Overview

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

Status:
Terminated

Trial end date:
2013-06-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to compare in an exploratory fashion the efficacy on progression-free survival of lanreotide in addition to non steroidal anti androgens and LHRH-a in non metastatic castrate resistant prostate cancer patients.

Phase:

Phase 3

Details

Lead Sponsor:

Ipsen

Treatments:

Androgen Antagonists
Androgens
Angiopeptin
Ascorbic Acid
Estrogens, Conjugated (USP)
Lanreotide
Methyltestosterone
Nonsteroidal Anti-Androgens
Prolactin Release-Inhibiting Factors
Somatostatin